LENZ (LENZ Therapeutics) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.89
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics LT-Debt-to-Total-Asset?

LENZ Therapeutics LENZ +1.73% 12 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. LENZ Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

LENZ Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.00) to Mar. 2026 (0.00). It may suggest that LENZ Therapeutics is progressively becoming less dependent on debt to grow their business.

LENZ Therapeutics  (NAS:LENZ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

LENZ Therapeutics LT-Debt-to-Total-Asset Related Terms

LENZ Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics LT-Debt-to-Total-Asset Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.00 0.00 0.00 0.00 0.00

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LENZ
12GF Score
LENZ Therapeutics Inc LENZ
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics LT-Debt-to-Total-Asset Calculation

LENZ Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.35/305.876
=0.00

LENZ Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.237/272.535
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
LENZ Therapeutics (LENZ) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on LENZ Therapeutics and its competitors.
Is LENZ Therapeutics' LT-Debt-to-Total-Asset too high?
LENZ Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' LT-Debt-to-Total-Asset compare to KRRO and ANTX?
LENZ Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on LENZ Therapeutics and its competitors. LENZ Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.89
Price